Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients by Borrill, Zoë L et al.
International Journal of COPD 2007:2(1) 71–76
© 2007 Dove Medical Press Limited.  All rights reserved
71
ORIGINAL RESEARCH
Variability of exhaled breath condensate 
leukotriene B4 and 8-isoprostane in COPD 
patients
Zoë L Borrill
R Cerys Starkey
S Dave Singh 
Medicines Evaluation Unit, Langley 
Building, Manchester University 
Wythenshawe Hospital, Manchester 
M23 9LT, UK
Correspondence: Zoë L Borrill
Medicines Evaluation Unit, Langley 
Building, Manchester University 
Wythenshawe Hospital, Manchester M23 
9LT, UK
Tel +44 161 946 4050/4073
Fax +44 161 946 1459
Email zborrill@meu.org.uk
Abstract: The reproducibility of exhaled breath condensate (EBC) mediators is not well 
documented in chronic obstructive pulmonary disease (COPD). This study assessed within assay 
(WA), within (WD) and between day (BD) reproducibility of EBC leukotriene B4 (LTB4) and 
8-isoprostane. Three EBC samples were collected from 24 COPD patients separated by 1 h and 1 
wk, to assess WD and BD reproducibility. WA reproducibility was assessed by sample analysis 
by enzyme immunoassay in triplicate. WA coefﬁ  cient of variation for LTB4 and 8-isoprostane 
(18.2% and 29.2%, respectively) was lower than corresponding values for WD (47.7% and 
65.3%, respectively) and BD (75.7% and 79.1%, respectively). Repeatability coefﬁ  cient for 
8-isoprostane and LTB4 assays were 18.6 pg/ml and 13.2 pg/ml, respectively. Group mean 
differences for WD and BD were small and statistically nonsigniﬁ  cant. Using the Bland Altman 
method, there were wide limits of agreement for WD (–51.6 to 47.2 for 8-isoprostane and –31.8 
to 31.4 for LTB4) and BD reproducibility (–61.4 to 75.7 for 8-isoprostane and –29.3 to 38.6 for 
LTB4). This is the ﬁ  rst study to fully report the variability of EBC 8-isoprostane and LTB4 in 
COPD. WA variability and group mean changes were small. However, we observed considerable 
WD and BD variability for these biomarkers. 
Keywords: chronic obstructive pulmonary disease, exhaled breath condensate, leukotriene B4, 
8-isoprostane, reproducibility.
Introduction
Biomarkers of airway inﬂ  ammation and oxidative stress can be measured noninvasively 
using exhaled breath condensate (EBC) sampling of airway lining ﬂ  uid. Leukotriene 
B4 (LTB4), a potent neutrophil chemoattractant, and 8-isoprostane, which is formed 
during oxidative stress conditions by free-radical peroxidation of arachidonic acid, 
are examples of biomarkers that have been measured in EBC from chronic obstructive 
pulmonary disease (COPD) patients. The absolute concentration of these mediators 
has varied greatly between studies, despite use of identical immunoassay methods. For 
example, mean values of LTB4 in COPD patients have ranged from 10 pg/ml (Biernacki 
et al 2003) to 100 pg/ml (Montuschi et al 2003). Similarly, mean values of 8-isopros-
tane in COPD patients have ranged from 9 pg/ml (Biernacki et al 2003) to 47 pg/ml 
(Kostikas et al 2003). The disparity between published ﬁ  ndings may be attributable 
to the small sample sizes often used, or to method variability. The reproducibility of 
EBC LTB4 and 8-isoprostane has not been well documented in COPD patients. This 
issue was highlighted as an important area for future research by the recent American 
Thoracic Society/European Respiratory Society (ATS/ERS) task force document on 
EBC methodology (Hovarth et al 2005). The current study was designed to investigate 
the variability of these mediators in COPD patients.  International Journal of COPD 2007:2(1) 72
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Methods
Twenty-four patients with COPD (16 male, mean age 65; 
10 current smokers, mean pack years 40; mean % predicted 
forced expiratory volume in one second [FEV1] 54% standard 
deviation [SD] 13.5%) diagnosed according to current criteria 
(NCCCC 2004) were recruited. Exclusion criteria were his-
tory of asthma or atopy, and respiratory tract infection within 
2 weeks of sample collection. Subjects were asked to refrain 
from caffeine and cigarettes for 2 hours prior to each visit. 
Written informed consent was obtained and the local ethics 
committee approved the study.
Three aspects of reproducibility were studied in all 
subjects: 1) Within day (WD) reproducibility was assessed 
by the collection of 2 samples of EBC separated by 1 h. 2) 
Between day (BD) reproducibility was assessed by the collec-
tion of a further EBC sample 1 week later; this measurement 
was compared with the ﬁ  rst collection one week earlier. 3) 
Within array (WA) reproducibility was assessed by analysis 
in triplicate of each sample. EBC was collected during tidal 
breathing for 10 minutes without a nose peg (EcoScreen, 
Jaegar, Hoechberg, Germany). Subjects were instructed to 
breathe normally through their mouth and to temporarily 
discontinue collection if they needed to swallow saliva or 
cough. Samples were aliquoted into separate 200 mcl tubes 
and frozen at –80ºC. LTB4 and 8-isoprostane were measured 
by enzyme immunoassays (Cayman Chemical, Ann Arbour, 
MI, USA). All samples were analysed in triplicate. The lower 
limits of detection were 13 pg/ml and 5 pg/ml for LTB4 and 
8-isoprostane respectively. Samples with a concentration be-
low the limit of the assay were assigned a level of 0 pg/ml.
Three statistical approaches were used to assess variabil-
ity: 1) Coefﬁ  cient of variation was used to assess WD, BD, 
and WA variability. 2) The repeatability coefﬁ  cient was used 
to analyse within assay variation; this estimated the limits of 
the differences that can be expected to occur between 95% 
of repeated assays performed on the same sample. Similarly, 
the Bland-Altman method with limits of agreement was used 
to assess WD and BD variability; this estimates the differ-
ences that can be expected to occur between 95% of samples 
collected at different times from the same subject (Bland and 
Altman 1986). The group mean and 95% conﬁ  dence intervals 
for the WD and BD differences were determined.
Results
The coefﬁ  cients of variation are shown in Table 1; the WA 
coefﬁ  cient of variation for both LTB4 and 8-isoprostane was 
lower than the corresponding values for WD and BD vari-
ability. The repeatability coefﬁ  cient for the 8-isoprostane 
assay was 18.6 pg/ml and for the LTB4 assay was 13.2 pg/ml. 
Group mean differences for WD and BD changes were small 
(Table 2). In contrast, the limits of agreement for WD and 
BD variability were large, demonstrating that levels of LTB4 
and 8-isoprostane can change markedly in some individuals 
even within 1 h (Table 2; Figure 1, 2). Limits of agreement 
for current smokers were in some cases wider than those for 
ex-smokers for both 8-isoprostane and LTB4 (Table 3).
Discussion
This is the ﬁ  rst study to fully report the variability of EBC 
8-isoprostane and LTB4 in COPD patients. Using the Bland 
Altman method, a robust technique for quantifying the po-
tential variability during repeated sampling from the same 
subject, we observed considerable WD and BD variability 
for these biomarkers. Previous studies using these biomark-
ers have either failed to investigate intra-subject variability 
or have reported variability as being ‘minimal’. There are 
several reasons why the variability of EBC mediators may 
have been underestimated in these studies. Firstly, EBC 
variability has been studied in healthy subjects (Csoma et al 
2002). It is probable that within subject variability in patients 
with lung inﬂ  ammation will be higher. Secondly, the use 
of the coefﬁ  cient of variation and correlation coefﬁ  cients 
provide statistics using arbitrary values that do not relate to 
the units of the measurement being studied. Thirdly, coef-
ﬁ  cient of variation, correlation coefﬁ  cients and group mean 
statistics provide information about overall group differences. 
These types of analysis do not inform us of the potential for 
Table 1 Coefﬁ  lcient of variation for within assay, within day, and 
between day variability
  Within assay  Within day  Between day
8-isoprostane 18.2%  49.7%  75.7%
LTB4 29.2% 65.3%  79.1%
Table 2 Mean difference (95% CI) and limits of agreement (LA) 
for within and between day variability of 8-isoprostane and LTB4 
in COPD 
 8-isoprostane    LTB4
 (pg/ml)  (pg/ml)
Within day mean        
  difference (95% CI)  –2.2 (–12.1 to 7.7)  –0.2 (–6.5 to 6.1) 
Within day LA  –51.6 to 47.2  –31.8 to 31.4
Between day mean      
  difference (95% CI)  7.1 (–6.6 to 20.8)   4.7 (–2.1 to 11.4) 
Between day LA  –61.4 to 75.7  –29.3 to 38.6
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary 
disease; LTB4, leukotriene B4.International Journal of COPD 2007:2(1) 73
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Figure 1 Bland Altman plots for (A) within day and (B) between day variability of EBC 8-isoprostane. Mean 8-isoprostane plotted against difference between 2 EBC samples 
taken 1 hour and 1 week apart.
Abbreviations: EBC, exhaled breath condensate.International Journal of COPD 2007:2(1) 74
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Figure 2 Bland Altman plots for (A) within day and (B) between day variability of EBC LTB4. Mean LTB4 plotted against difference between 2 EBC samples taken 1 hour and 
1 week apart.
Abbreviations: EBC, exhaled breath condensate; LTB4, leukotriene B4.
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repeated samples from a single individual to vary over time. 
In the current study we observed no signiﬁ  cant change in the 
group mean values over time. This does not mean that there 
was no variability; the Bland Altman method graphically 
shows that while some individuals have highly reproducible 
measurements over time, there was considerable variation 
in the samples from other subjects, which contributed to the 
wide limits of agreements. The interpretation of the limits 
of agreements is, for example, that repeated 8-isoprostane 
sampling on different days can be expected to vary from 
–61.4 pg/ml to 75.7 pg/ml in an individual simply due to 
natural variability. Using this assay as a biomarker to detect 
a signiﬁ  cant biological change (greater than assay variability) 
in an individual, such as an exacerbation, would require a 
change greater than these limits of agreement. 
The variability observed in this study may be explained 
either by (1) true changes in the composition of the airway 
lining ﬂ  uid, (2) variability due to the sample collection meth-
odology, or (3) the variability of the immunoassay method 
used to analyse the sample. The contribution of these 3 
factors will now be considered: 1) We have recently shown 
marked WD and BD variability of EBC pH in COPD patients 
compared with that seen in healthy subjects, indicating that 
there are changes in the composition of EBC in COPD 
patients over time (Borrill et al 2005). In the current study, 
there was some evidence of greater variability in current 
smokers compared with ex-smokers. Acute smoking was 
found to cause an increase in EBC 8-isoprostane after 15 
minutes, but not at 5 h (Montuschi et al 2000). In the current 
study, variation in the time since the last cigarette may have 
contributed to the variability observed. 2) Inconsistencies in 
the rate of aerosolization of airway lining ﬂ  uid during sample 
collection may lead to increased variability. Attempts have 
been made to correct for this using dilution factors (Effros 
et al 2003) and further study in this area is required. 3) The 
coefﬁ  cient of variation showed lower within assay variabil-
ity for both LTB4 and 8-isoprostane compared with within 
subject variation. This was conﬁ  rmed by the repeatability 
coefﬁ  cients for each assay which were lower than the limits 
of agreement between samples. The numerical value of the 
repeatability coefﬁ  cient can be considered to be equivalent 
to the magnitude of the limits of agreement, which enables 
direct comparison. This indicates that the repeatability of the 
assay itself cannot fully explain the degree of within subject 
variability observed. 
In a study by van Hoydonk and colleagues (2004), 
8-isoprostane was undetectable in 21 of the 36 samples from 
healthy smokers. In the current study 8-isoprostane was de-
tectable in all COPD samples. However, levels of LTB4 were 
below the limit of detection in a large number of samples, 
which may indicate the poor sensitivity of this assay. In a 
study by Carpagnano and colleagues (2003) some samples 
had levels which were below the limit of detection of the as-
say. This suggests that the authors either diluted the standard 
below the level recommended, or that they extrapolated the 
standard curve below the lowest concentration of standard. 
These are not standard practices for immunoassays and are 
likely to lead to a loss of accuracy. To avoid these potential 
errors, we deﬁ  ned the lower limit of detection of the assay 
as the lowest concentration on the standard curve. Methods 
such as mass spectroscopy may offer advantages over im-
munoassays in terms of increased sensitivity and reduced 
variability (Cap et al 2004; Montuschi et al 2004).  
Overall, it is likely that the variability we have reported 
is multifactorial, with changes in the composition of the 
airway lining ﬂ  uid, variability due to the sample collection 
methodology, and immunoassay variability and sensitivity 
all contributing. The high level of variability observed casts 
doubt on the current EBC methodology used to assess LTB4 
and 8-isoprostane. Our study highlights the importance of 
assessing method variability. Differences between patients 
with disease and controls can only be properly evaluated with 
knowledge of the variability of the method. 
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